there’s no doubt it looks promising and a response rate of 6/14 (43%) is on the face of it better than the MPACT trial (23%) but I’m always cautious of making comparisons between two very uneven groups. This is n=14 vs n=430 in MPACT gem/abrax arm. 30 fold difference!
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-8
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.59M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.5¢ | 14.5¢ | $78.75K | 518.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3340 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 97318 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| ATX (ASX) Chart |